Weight Changes on Vilazodone

Naomi Carr
Brittany Ferri
Written by Naomi Carr on 10 February 2026
Medically reviewed by Brittany Ferri on 15 February 2026

Vilazodone is an antidepressant medication used to treat major depressive disorder. Although it is one of the least likely antidepressants to cause weight changes, some people who use it may experience slight weight gain. People using vilazodone can incorporate changes into their lifestyle or treatment plan to help manage any weight changes.

Key takeaways:
  • Vilazodone is an antidepressant medication classified as a serotonin partial agonist and reuptake inhibitor (SPARI).
  • Vilazodone is unlikely to cause weight changes, although some people may experience some weight gain or loss.
  • During vilazodone treatment, people can utilize lifestyle changes or adjunctive medications to help manage any weight gain.
A close up photo of Vilazodone tablets inside a pill box with a measuring tape wrapped around the pill box

Does vilazodone cause weight gain?

Like many antidepressants and psychotropic medications, vilazodone (Viibryd) may lead to changes in weight for some people, including weight gain. However, vilazodone is found to be one of the least likely antidepressants to cause weight gain and is commonly associated with no significant change in weight during treatment.

This can differ between individuals and may depend on several factors. As such, there may be people who gain weight, lose weight, or notice no change in weight during vilazodone treatment.

Average weight changes

Various studies have been conducted to ascertain the level of weight change with vilazodone treatment. Generally, these studies indicate that weight remains fairly stable throughout treatment. One study indicates an average of 1.7kg increase over one year.

Why some people gain or lose weight on vilazodone

Various mechanisms associated with antidepressant use can be linked to changes in weight. For example, long-term use can cause an accumulation of serotonin in the synaptic cleft, which can lead to a down-regulation or desensitization of 5-HT2 receptors. This might lead to an increase in appetite and weight for some people.

Additionally, there is some evidence that long-term selective serotonin reuptake inhibitor (SSRI) use causes an increase in cravings for carbohydrates, which can lead to weight gain with increased consumption.

These mechanisms may also be present with SPARI medications such as vilazodone, although weight changes are less likely with vilazodone than with SSRIs and other antidepressants. This is likely due to its unique mechanism of action as a serotonin partial agonist reuptake inhibitor (SPARI).

Individual factors

Weight changes can also occur with antidepressant treatment because of the individual’s changes in symptom presentation. Appetite changes are a common symptom of depression. 

Medications, such as vilazodone, aim to treat depression symptoms, including appetite changes. As such, someone who eats less during a depressive episode might notice that their appetite increases once their condition is treated, and someone who tends to eat more during a depressive episode might find that their appetite decreases.

Because of this, weight changes while on an antidepressant might not simply be due to the medication's effects on the body or metabolism, but also because of the changes in depressive symptoms. Additionally, genetic, environmental, and lifestyle factors can influence a person’s likelihood of losing or gaining weight during treatment.

Is vilazodone more weight-neutral than other antidepressants?

Studies indicate that vilazodone is less likely than other antidepressants to cause weight gain. Research suggests that vilazodone causes little or no change in weight.

One study shows an increase of 0.2 kg after 8 weeks and 1.7 kg after one year of vilazodone treatment. However, this is much lower than SSRI treatment, which shows an average weight increase of 6.8 to 10.8 kg in the same time period.

Research indicates that some of the antidepressants most likely to cause weight gain include:

Aside from vilazodone, the antidepressants least likely to cause weight gain include:

  • Levomilnacipran: An SNRI with no significant change in weight long term.
  • Vortioxetine: An SSRI causing no significant change in weight for many. A small number of individuals saw a very slight increase of 0.41 kg over one year. 
  • Bupropion: Unlikely to cause weight gain and may even lead to some weight loss.
  • Fluoxetine: Fluoxetine may cause some weight loss initially, with weight stabilization as treatment continues.

Managing weight changes on vilazodone

People utilizing vilazodone treatment can prevent or manage weight changes by:

Should you stop vilazodone because of weight gain?

If weight gain is significant and is impacting self-esteem and well-being, it might be appropriate to make some treatment changes. However, it is important to gauge the benefits and risks of all medications. If a treatment is effective, it might be more suitable to try to manage unpleasant effects with other strategies than to stop the medication.

People who experience significant weight gain might wish to change their medication, and this should only be done with professional advice. Never stop or alter your medication without guidance from a physician, as adverse effects, withdrawal symptoms, and unmanaged symptoms can occur. It may be necessary to gradually reduce vilazodone before commencing an alternative medication.

When to seek medical help

People taking vilazodone should receive a regular medication review with their prescribing physician to ensure the safety and effectiveness of the medication, discuss and manage adverse effects, and monitor symptom changes. Outside of these reviews, individuals may wish to seek medical help if they experience:

Failing to seek treatment in these situations may increase the risk of serious complications, including worsening mental health symptoms, medication toxicity, serotonin syndrome, or unsafe drug interactions. Prompt medical evaluation can help prevent further harm and ensure appropriate adjustments to care.

Was this page helpful?

Your feedback allows us to continually improve our information

Resources:

  1. Liebowitz, M., Croft, H.A., Kajdasz, D.K., Whalen, H., Gallipoli, S., Athanasiou, M., & Reed, C.R. (2011). The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder. Psychopharmacology Bulletin, 44(3), 15–33. Retrieved from
  2. Schwartz, T.L., Siddiqui, U.A., & Stahl, S.M. (2011). Vilazodone: A Brief Pharmacological and Clinical Review of the Novel Serotonin Partial Agonist and Reuptake Inhibitor. Therapeutic Advances in Psychopharmacology, 1(3), 81–87. Retrieved from
  3. Robinson, D.S., Kajdasz, D.K., Gallipoli, S., Whalen, H., Wamil, A., & Reed, C.R. (2011). A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major Depressive Disorder. Journal of Clinical Psychopharmacology, 31(5), 643–646. Retrieved from
  4. MacDaniels, J.S., & Schwartz, T.L. (2016). How to Control Weight Gain when Prescribing Antidepressants. Current Psychiatry, 15(6), 30-48. Retrieved from
  5. Mouawad, M., Nabipur, L., & Agrawal, D.K. (2025). Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies. Archives of Clinical and Biomedical Research, 9(3), 183–195. Retrieved from
  6. Serretti, A., & Mandelli, L. (2010). Antidepressants and Body Weight: A Comprehensive Review and Meta-Analysis. The Journal of Clinical Psychiatry, 71(10), 1259–1272. Retrieved from
  7. Alonso-Pedrero, L., Bes-Rastrollo, M., & Marti, A. (2019). Effects of Antidepressant and Antipsychotic Use on Weight Gain: A Systematic Review. Obesity Reviews: An Official Journal of the International Association for the Study of Obesity, 20(12), 1680–1690. Retrieved from
  8. Jacobsen, P.L., Harper, L., Chrones, L., Chan, S., & Mahableshwarkar, A.R. (2015). Safety and Tolerability of Vortioxetine (15 and 20 mg) in Patients with Major Depressive Disorder: Results of an Open-Label, Flexible-Dose, 52-Week Extension Study. International Clinical Psychopharmacology, 30(5), 255–264. Retrieved from

Activity History - Last updated: 15 February 2026, Published date:


Reviewer

Brittany Ferri

PhD, OTR/L

Brittany Ferri holds a PhD in Integrative Mental Health and is an occupational therapist, health writer, medical reviewer, and book author.

Activity History - Medically Reviewed on 10 February 2026 and last checked on 15 February 2026

Medically reviewed by
Brittany Ferri

Brittany Ferri

PhD, OTR/L

Reviewer

Recovered Branding BG
Ready to talk about treatment? Call today. (833) 840-1202
Helpline Information

Calls to numbers marked with (I) symbols will be answered or returned by one of the treatment providers listed in our Terms and Conditions, each of which is a paid advertiser.

In calling the helpline you agree to our Terms and Conditions. We do not receive any fee or commission dependent upon which treatment or provider a caller chooses.

There is no obligation to enter treatment.

Access State-Specific Provider Directories for detailed information on locating licensed service providers and recovery residences in your area.

For any specific questions please email us at info@recovered.org